| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.30▲ | 1.32▼ | 1.33▼ | 1.44▼ | 1.41▼ |
| MA10 | 1.31▲ | 1.34▼ | 1.35▼ | 1.46▼ | 1.16▲ |
| MA20 | 1.33▼ | 1.36▼ | 1.40▼ | 1.45▼ | 1.07▲ |
| MA50 | 1.37▼ | 1.45▼ | 1.46▼ | 1.14▲ | 1.85▼ |
| MA100 | 1.44▼ | 1.46▼ | 1.47▼ | 1.06▲ | 1.51▼ |
| MA200 | 1.47▼ | 1.44▼ | 1.30▲ | 1.56▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.001▼ | -0.002▼ | -0.008▼ | -0.035▼ | 0.105▲ |
| RSI | 42.570▼ | 38.166▼ | 27.092▼ | 48.641▼ | 50.704▲ |
| STOCH | 19.697▼ | 17.458▼ | 26.047 | 34.780 | 50.713 |
| WILL %R | -60.000 | -77.778▼ | -78.571▼ | -88.095▼ | -52.388 |
| CCI | -52.628 | -110.303▼ | -136.279▼ | -190.529▼ | 72.538 |
|
Wednesday, November 05, 2025 05:46 AM
This strategic filing with the FDA follows encouraging internal data and recent published studies supporting Nexalin’s frequency neurostimulator as a potential non-invasive therapy for cognitive ...
|
|
Wednesday, November 05, 2025 05:46 AM
Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that the U.S. Food and Drug ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 05/11/25 | 1.40 | 1.45 | 1.27 | 1.32 | 1,826,733 |
| 04/11/25 | 1.43 | 1.43 | 1.36 | 1.38 | 305,478 |
| 03/11/25 | 1.47 | 1.50 | 1.44 | 1.47 | 285,100 |
| 31/10/25 | 1.52 | 1.60 | 1.47 | 1.50 | 301,270 |
| 30/10/25 | 1.55 | 1.65 | 1.50 | 1.53 | 470,800 |
| 29/10/25 | 1.47 | 1.58 | 1.44 | 1.55 | 407,850 |
| 28/10/25 | 1.50 | 1.5396 | 1.45 | 1.48 | 194,010 |
| 27/10/25 | 1.46 | 1.54 | 1.43 | 1.48 | 204,500 |
| 24/10/25 | 1.46 | 1.49 | 1.42 | 1.44 | 330,300 |
| 23/10/25 | 1.54 | 1.54 | 1.42 | 1.48 | 276,300 |
|
|
||||
|
|
||||
|
|